AR057332A1 - Tienopiridinas, procedimientos de obtencion y composiciones farmaceuticas - Google Patents
Tienopiridinas, procedimientos de obtencion y composiciones farmaceuticasInfo
- Publication number
- AR057332A1 AR057332A1 ARP060102182A ARP060102182A AR057332A1 AR 057332 A1 AR057332 A1 AR 057332A1 AR P060102182 A ARP060102182 A AR P060102182A AR P060102182 A ARP060102182 A AR P060102182A AR 057332 A1 AR057332 A1 AR 057332A1
- Authority
- AR
- Argentina
- Prior art keywords
- hal
- nha
- so2a
- naa
- mono
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 6
- 125000000565 sulfonamide group Chemical group 0.000 abstract 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 2
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 235000010290 biphenyl Nutrition 0.000 abstract 2
- 239000004305 biphenyl Substances 0.000 abstract 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 2
- -1 methylenedioxy Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 1
- 240000000543 Pentas lanceolata Species 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
Abstract
Son inhibidores de las HSP90 y pueden ser utilizados para preparar un medicamento para el tratamiento de enfermedades en las que la inhibicion, la regulacion y/o la modulacion de la HSP90 desempenan un papel importante. Reivindicacion 1: Compuestos de la formula (1), en donde, Y es OH, OA, SH, SA, NH2, NHA, NAA' o NHR5; R1 es Hal, OH, OA, SH, SA, H o A; R2, R3 son en cada caso, de modo independiente entre sí, -NHCO-(X)s-Q, -CONH-(X)s-Q, -CONA-(X)s-Q, -NH(CO)NH-(X)s-Q, -NH(CO)O-(X)s-Q, -NHSO2- (X)s-Q, -SO2NH-(X)s-Q, -SO2NA-(X)s-Q, -(X)s-Q o H, en donde, en caso de que R2 (distinto) H, entonces R3 = H o Cl, o en caso de que R3 (distinto) H, entonces R2 = H o Cl; R4 es H, Hal, CN, NO2, A, OH, OA, SH, SA, (CH2)nCOOH, (CH2)nCOOA, CONH2, CONHA, CONAA', NH2, NHA, NAA', NHCOOA, NHCONH2, NHCONHA, SOA, SO2A, SO2NH2, SO2NHA y/o SO2NAA', dos radicales adyacentes, seleccionados del grupo R1, R2, R3, R4 también son juntos metilendioxi o etilendioxi; R5 es -(CH2)o-Het1, -(CH2)o-NH2, -(CH2)o- NHA o -(CH2)o-NA2; A, A' son en cada caso, de modo independiente entre sí, alquilo C1-10 no ramificado o ramificado, en donde 1-5 átomos de H pueden estar reemplazados por F, Cl y/o Br; Alk o alquilo cíclico con C3-7; A y A' también son juntos una cadena alquileno con 2, 3, 4, 5 o 6 átomos de C, en donde uno o dos grupos CH2 pueden estar reemplazados por O, SO, SO2, NH, NA y/o N-COOA; Alk es alquileno C2-6; X es alquileno C1-10 o alquenileno C2-10 no ramificado o ramificado no sustituido o mono-, di-, tri- o tetrasustituido con A, OA, OH, SH, SA, Hal, NO2, CN, Ar, OAr, COOH, COOA, CHO, C(=O)A, C(=O)Ar, SO2A, CONH2, SO2NH2, CONHA, CONAA', SO2NHA, SO2NAA', NH2, NHA, NAA', OCONH2, OCONHA, OCONAA', NHCOA, NHCOOA, NACOOA, NHSO2OA, NASO2OA, NHCONH2, NACONH2, NHCONHA, NACONHA, NHCONAA', NACONAA' y/u =O, en donde también uno, dos o tres grupos C pueden estar reemplazados por O, S, SO, SO2, NHCO, NACO, CONH, CONA, SO2NH, SO2NA, NHSO2, NASO2 y/o por grupos NH; Q es H, Carb, Ar o Het; Carb es cicloalquilo C3-7 o cicloalquenilo C3-7 no sustituido o mono-, di-, tri-, tetra- o pentasustituido con A, OA, OH, SH, SA, Hal, NO2, CN, (CH2)nAr', (CH2)nCOOH, (CH2)nCOOA, CHO, COA, SO2A, CONH2, SO2NH2, CONHA, CONAA', SO2NHA, SO2NAA', NH2, NHA, NAA', OCONH2, OCONHA, OCONAA', NHCOA, NHCOOA, NACOOA, NHSO2OA, NASO2OA, NHCONH2, NACONH2, NHCONHA, NACONHA, NHCONAA' y/o NACONAA'; Ar es fenilo, naftilo o bifenilo no sustituido o mono-, di-, tri- tetra- o pentasustituido con A, OA, OH, SH, SA, Hal, NO2, CN, (CH2)nAr', (CH2)nCOOH, (CH2)nCOOA, CHO, COA, SO2A, CONH2, SO2NH2, CONHA, CONAA', SO2NHA, SO2NAA', NH2, NHA, NAA', OCONH2, OCONHA, OCONAA', NHCOA, NHCOOA, NACOOA, NHSO2OA, NASO2OA, NHCONH2, NACONH2, NHCONHA, NACONHA, NHCONAA', NACONAA', NHCO(CH2)nNH2 y/u -O-(CH2)o-Het1; Ar' es fenilo, naftilo o bifenilo no sustituido o mono-, di- o trisustituido con A, OA, OH, SH, SA, Hal, NO2, CN, (CH2)nfenilo, (CH2)nCOOH, (CH2)nCOOA, CHO, COA, SO2A, CONH2, SO2NH2, CONHA, CONAA', SO2NHA, SO2NAA', NH2, NHA, NAA', OCONH2, OCONHA, OCONAA', NHCOA, NHCOOA, NACOOA, NHSO2OA, NASO2OA, NHCONH2, NACONH2, NHCONHA, NACONHA, NHCONAA' y/o NACONAA'; Het es un heterociclo mono- o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede estar mono-, di- o trisustituido con A, OA, OH, SH, SA, Hal, NO2, CN, (CH2)nAr', (CH2)nCOOH, (CH2)nCOOA, CHO, COA, SO2A, CONH2, SO2NH2, CONHA, CONAA', SO2NHA, SO2NAA', NH2, NHA, NAA', OCONH2, OCONHA, OCONAA', NHCOA, NHCOOA, NACOOA, NHSO2OA, NASO2OA, NHCONH2, NACONH2, NHCONHA, NACONHA, NHCONAA', NACONAA', SO2A, =S, =NH, =NA y/u =O (oxígeno del carbonilo); Het1 es un heterociclo saturado monocíclico con 1 a 2 átomos de N y/u O, que puede estar mono- o disustituido con A, OA, OH, Hal y/o =O (oxígeno del carbonilo); Hal es F, Cl, Br o I; n es 0, 1, 2, 3 o 4; o es 1, 2, 3 o 4; s 0 o 1; así como sus derivados, sales, solvatos, tautomeros y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005024245A DE102005024245A1 (de) | 2005-05-27 | 2005-05-27 | Thienopyridine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057332A1 true AR057332A1 (es) | 2007-11-28 |
Family
ID=36660679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102182A AR057332A1 (es) | 2005-05-27 | 2006-05-26 | Tienopiridinas, procedimientos de obtencion y composiciones farmaceuticas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7989625B2 (es) |
| EP (1) | EP1888593A2 (es) |
| JP (1) | JP2008542213A (es) |
| KR (1) | KR20080021054A (es) |
| CN (1) | CN101163707A (es) |
| AR (1) | AR057332A1 (es) |
| AU (1) | AU2006251420A1 (es) |
| BR (1) | BRPI0610204A2 (es) |
| CA (1) | CA2609385A1 (es) |
| DE (1) | DE102005024245A1 (es) |
| MX (1) | MX2007014720A (es) |
| RU (1) | RU2415859C2 (es) |
| WO (1) | WO2006125531A2 (es) |
| ZA (1) | ZA200711142B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007049451A1 (de) | 2007-10-16 | 2009-04-23 | Merck Patent Gmbh | 5-Cyano-thienopyridine |
| US20090118276A1 (en) * | 2007-11-02 | 2009-05-07 | Wyeth | Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors |
| GB0908394D0 (en) * | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| CN102933390B (zh) | 2010-09-13 | 2017-02-08 | 艾利丹尼森公司 | 用于热密封包装的可再密封的层压材料 |
| TWI458732B (zh) * | 2012-06-27 | 2014-11-01 | Univ Nat Chiao Tung | 具硼酸基團連接子及含有其之生物感測元件 |
| ES2779748T3 (es) | 2012-08-23 | 2020-08-19 | Janssen Biopharma Inc | Compuestos para el tratamiento de infecciones víricas por paramixovirus |
| MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
| WO2023213761A1 (en) * | 2022-05-03 | 2023-11-09 | Universite De Geneve | Adenosine 2a receptor modulators for use in the treatment of cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0323810D0 (en) * | 2003-10-10 | 2003-11-12 | Cancer Rec Tech Ltd | Pyridothiophene compounds |
| WO2005058315A1 (en) * | 2003-12-12 | 2005-06-30 | Ribapharm, Inc. | Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity |
| DE102005009440A1 (de) * | 2005-03-02 | 2006-09-07 | Merck Patent Gmbh | Thienopyridinderivate |
-
2005
- 2005-05-27 DE DE102005024245A patent/DE102005024245A1/de not_active Withdrawn
-
2006
- 2006-05-11 EP EP06724792A patent/EP1888593A2/de not_active Withdrawn
- 2006-05-11 MX MX2007014720A patent/MX2007014720A/es active IP Right Grant
- 2006-05-11 AU AU2006251420A patent/AU2006251420A1/en not_active Abandoned
- 2006-05-11 JP JP2008512724A patent/JP2008542213A/ja active Pending
- 2006-05-11 WO PCT/EP2006/004426 patent/WO2006125531A2/de active Application Filing
- 2006-05-11 CN CNA2006800138250A patent/CN101163707A/zh active Pending
- 2006-05-11 RU RU2007147593/04A patent/RU2415859C2/ru not_active IP Right Cessation
- 2006-05-11 BR BRPI0610204-2A patent/BRPI0610204A2/pt not_active IP Right Cessation
- 2006-05-11 US US11/915,486 patent/US7989625B2/en not_active Expired - Fee Related
- 2006-05-11 KR KR1020077030243A patent/KR20080021054A/ko not_active Application Discontinuation
- 2006-05-11 CA CA002609385A patent/CA2609385A1/en not_active Abandoned
- 2006-05-26 AR ARP060102182A patent/AR057332A1/es unknown
-
2007
- 2007-12-20 ZA ZA200711142A patent/ZA200711142B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2415859C2 (ru) | 2011-04-10 |
| WO2006125531A3 (de) | 2007-04-12 |
| MX2007014720A (es) | 2008-02-15 |
| BRPI0610204A2 (pt) | 2010-06-01 |
| CA2609385A1 (en) | 2006-11-30 |
| RU2007147593A (ru) | 2009-07-10 |
| ZA200711142B (en) | 2008-11-26 |
| AU2006251420A1 (en) | 2006-11-30 |
| JP2008542213A (ja) | 2008-11-27 |
| DE102005024245A1 (de) | 2006-11-30 |
| US20100048558A1 (en) | 2010-02-25 |
| WO2006125531A2 (de) | 2006-11-30 |
| KR20080021054A (ko) | 2008-03-06 |
| EP1888593A2 (de) | 2008-02-20 |
| US7989625B2 (en) | 2011-08-02 |
| CN101163707A (zh) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057332A1 (es) | Tienopiridinas, procedimientos de obtencion y composiciones farmaceuticas | |
| AR054047A1 (es) | Derivados de fenilquinazolina | |
| AR067082A1 (es) | Derivados de indazolamida, proceso de preparacion, medicamentos que los contienen y usos de los mismos, fundamentalmente, como agentes antitumorales y/o antivirales. | |
| AR067506A1 (es) | Derivados de quinazolinamida | |
| AR061009A1 (es) | 1,2-difenil-pirazoles i i como inhibidores de hsp90 | |
| AR061735A1 (es) | Derivados de indazol, composiciones farmaceuticas y uso de los mismos | |
| AR070649A1 (es) | Derivados de 1,3- dihidro -isoindol | |
| AR090602A1 (es) | AMIDAS CICLICAS Y HETEROCICLOS COMO INHIBIDORES DE MetAP-2 | |
| AR082722A1 (es) | Derivados de pirimidina | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| AR077488A1 (es) | Compuestos heterociclicos nitrogenados inhibidores de autotaxina, medicamentos que los contienen y uso de los mismos para el tratamiento y/o prevencion de cancer y enfermedades tumorales. | |
| AR061010A1 (es) | Derivados de triazol i i | |
| AR082726A1 (es) | Derivados de triazolopirazina | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| AR089945A1 (es) | DERIVADOS DE FURO[3,2-B] Y TIENO[3,2-B]PIRIDINA COMO MODULADORES DE TBK1 E IKKe | |
| AR074493A1 (es) | Derivados de quinazolinamida | |
| AR064952A1 (es) | Derivados de 5-([1, 3, 4]oxadiazol-2-il)-1h-indazol y 5-([1, 3, 4]tiadiazol-2-il)-1h-indazol, un metodo para su preperacion, un kit de elementos que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la sgk. | |
| AR052482A1 (es) | Derivados de triazol como inhibidores de hsp90 | |
| AR066557A1 (es) | Derivados de 1h-indazol-5-il-[1, 3, 4]oxadiazol-2-ilo, un metodo para su preparacion, y el uso de los mismos en medicamentos para el tratamiento de enfermedades mediadas por la modulacion de la sgk. | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR058205A1 (es) | 5-fenil-3,6-dihidro-2-oxo-6h-[1,3,4] tiadiazinas sustituidas | |
| AR045407A1 (es) | Compuesto de tiazolidin-4-ona, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| CO6160288A2 (es) | Composiciones farmaceuticas que comprenden nilotinib o su sal | |
| AR081828A1 (es) | Compuestos de biguanida y su uso para el tratamiento del cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |